Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $60.00

Stoke Therapeutics (NASDAQ:STOK) had its price target boosted by Canaccord Genuity Group from $36.00 to $60.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also weighed in on STOK. Chardan Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. Needham & Company LLC upped their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Guggenheim initiated coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective for the company. Wolfe Research began coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, HC Wainwright upped their price target on Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics Trading Up 1.0%

NASDAQ STOK opened at $33.51 on Friday. The stock has a fifty day simple moving average of $32.61 and a 200-day simple moving average of $30.17. The stock has a market cap of $1.98 billion, a PE ratio of 50.01 and a beta of 1.07. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $40.22.

Insiders Place Their Bets

In related news, General Counsel Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $145,041.52. Following the completion of the transaction, the general counsel owned 28,836 shares in the company, valued at approximately $903,720.24. The trade was a 13.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 6,686 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $209,539.24. Following the sale, the insider directly owned 40,798 shares in the company, valued at approximately $1,278,609.32. The trade was a 14.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 69,699 shares of company stock valued at $2,526,714. 9.50% of the stock is owned by company insiders.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently modified their holdings of the stock. RTW Investments LP raised its stake in shares of Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock valued at $176,057,000 after acquiring an additional 423,331 shares in the last quarter. Morgan Stanley grew its stake in Stoke Therapeutics by 0.3% during the 4th quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after purchasing an additional 9,108 shares in the last quarter. Vanguard Group Inc. increased its holdings in Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after purchasing an additional 217,616 shares during the period. State Street Corp increased its holdings in Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after purchasing an additional 1,072,176 shares during the period. Finally, Marshall Wace LLP raised its position in Stoke Therapeutics by 7.9% in the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after purchasing an additional 168,771 shares in the last quarter.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.